Cyntegrity

Cyntegrity delivers AI-augmented, risk-based quality management that keeps BioPharma trials compliant, predictable, and cost-efficient. Since embedding machine-learning predictors into the MyRBQM® Portal in 2017, we have steadily broadened our engine: first scaling predictive analytics across every clinical metric by 2020, then unveiling Ask AI for real-time risk assessment and inspection readiness in 2023, and in 2024, extending our suite with AI-driven clinical due-diligence support.

In 2025, we earned Microsoft’s Healthcare AI certification and launched protocol-complexity and portfolio-risk modules, further sharpening our decision support.Today, the MyRBQM® Portal, Academy, and FSP offerings combine SaaS, education, and embedded expertise to help sponsors, CROs, regulators, and auditors focus resources where they matter most, all under ICH E6(R3), E8(R1), and Q9(R1) guidelines. Powered by a multicultural team spanning 17 nationalities in 14 countries and backed by 11 years of exclusive RBQM focus, Cyntegrity remains the partner of choice for data-driven clinical-trial oversight, change enablement and regulator-ready performance.